Fulcrum Therapeutics' stock dropped nearly 50% in after-hours trading after the company announced it is discontinuing its lead experimental drug, pociredir, for sickle cell disease. The decision follows FDA concerns about cancer risks linked to the drug's target pathway, leaving no regulatory path forward. Fulcrum is now conducting a strategic review, considering options like mergers or acquisitions, while cutting costs to preserve capital. The company holds $333.3 million in cash and securities as it evaluates its future direction.
Inventiva, a clinical-stage biopharmaceutical company, has temporarily suspended trading of its ordinary shares on Euronext Paris starting June 2, 2026, at 9:00 CEST. This suspension is at the company's request and precedes a planned financing operat...
Inventiva, a clinical-stage biopharmaceutical company, has temporarily halted trading of its ordinary shares on Euronext Paris starting June 2, 2026, at 9:00 a.m. CEST. This pause is at the company's request and precedes a proposed financing transact...
The FDA has accepted Roche's New Drug Application for giredestrant, an oral selective estrogen receptor degrader (SERD), as an adjuvant treatment for early-stage ER-positive, HER2-negative breast cancer. The approval decision is expected by November ...
dsm-firmenich announced ongoing progress in its share repurchase program, buying back 184,000 shares between May 25-29, 2026, at an average price of €72.36 per share, totaling €13.3 million. This is part of a larger €540 million buyback initiated in ...
Sika has appointed Philipp Irniger as the new Head of Construction and member of Group Management, succeeding Ivo Schädler who will retire in March 2027. Irniger brings extensive international experience and will lead Sika's global construction busin...
